| Customization: | Available |
|---|---|
| CAS No.: | 223673-61-8 |
| Formula: | C21h24n4o2s |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product name: Mirabegron
CAS No: 223673-61-8
Mirabegron is a selective beta-3 adrenergic receptor agonist used in the treatment of overactive bladder (OAB) syndrome. It works by stimulating the beta-3 adrenergic receptors in the bladder's detrusor muscle, leading to muscle relaxation, increased bladder capacity, and reduced frequency of urination. Mirabegron is a white to off-white crystalline powder that is highly soluble in organic solvents and is typically administered orally in tablet form. It is known for its effectiveness in managing symptoms of OAB without causing the common anticholinergic side effects.
Application and Effect
Mirabegron is primarily prescribed to treat overactive bladder (OAB), a condition characterized by symptoms such as frequent urination, urgency, and incontinence. By selectively activating the beta-3 adrenergic receptors in the bladder muscle, Mirabegron helps relax the detrusor muscle, thereby increasing bladder capacity and reducing the need for frequent urination. This mechanism of action provides significant relief for individuals suffering from OAB, improving their quality of life and urinary control. One of the key advantages of Mirabegron over traditional treatments for OAB, such as antimuscarinic agents, is that it does not cause the common anticholinergic side effects like dry mouth, constipation, or blurred vision. This makes it a suitable option for patients who are intolerant to anticholinergic medications. Additionally, Mirabegron has shown to be effective in both male and female patients with OAB, making it a widely applicable treatment. Mirabegron is also being investigated for other potential uses, including its application in the management of urinary retention and as a potential adjunct therapy for other lower urinary tract disorders. While Mirabegron is generally well-tolerated, it may cause mild side effects such as increased blood pressure, headache, and dizziness. As with any medication, careful monitoring and individualized treatment plans are essential to ensure its optimal use, particularly in patients with preexisting cardiovascular conditions.
Specifications:
| Composition | C21H24N4O2S |
| Assay | 99% |
| Appearance | White to light yellow solid |
| CAS No. | 223673-61-8 |
| Packing | Small and bulk |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |
){kind=link}